Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of WIBP-CorV in Elderly with Chronic Bronchitis or COPD
NCT05075057Phase 4Unknown
- Sponsor
- China National Biotec Group
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of inactivated SARS-CoV-2 vaccine (WIBP) in coronavirus disease 2019 (COVID-19), sponsored by China National Biotec Group. Primary endpoints: Seroconversion rate at Day 139 and Neutralizing antibody level at Day 291. Status: unknown.
02
Drugs
inactivated SARS-CoV-2 vaccine (WIBP)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05075057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075057.